TP53 and hepatocellular carcinoma: This phenomenon implied deactivation of RBM38 may promote mdm2, then consequently inhibit p53 and finally disrupt the p53-mdm2 loop function at the posttranscriptional level and promote HCC, even though p53 and mdm2 transcript amounts were stable.